Popular Filters
Trials for Thyroid Gland Carcinoma Patients
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
Kinase Inhibitor
Everolimus + Sorafenib for Thyroid Cancer
This trial is testing a combination of two pills, sorafenib and everolimus, to treat thyroid cancer. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps cancer cells grow. Everolimus is approved for various cancers, including breast cancer, and has shown promise in combination therapies. The study aims to see if this combination works better than current treatments.
Trials for Thyroid Nodule Patients
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
Kinase Inhibitor
Everolimus + Sorafenib for Thyroid Cancer
This trial is testing a combination of two pills, sorafenib and everolimus, to treat thyroid cancer. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps cancer cells grow. Everolimus is approved for various cancers, including breast cancer, and has shown promise in combination therapies. The study aims to see if this combination works better than current treatments.
Trials for Metastatic Patients
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
Kinase Inhibitor
Everolimus + Sorafenib for Thyroid Cancer
This trial is testing a combination of two pills, sorafenib and everolimus, to treat thyroid cancer. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps cancer cells grow. Everolimus is approved for various cancers, including breast cancer, and has shown promise in combination therapies. The study aims to see if this combination works better than current treatments.
Alkylating agents
Cyclophosphamide + Sirolimus for Advanced Thyroid Cancer
This trial uses two drugs, Cyclophosphamide and Sirolimus, to treat patients with thyroid cancer that has spread. Cyclophosphamide kills cancer cells by breaking their DNA, while Sirolimus stops them from growing. Sirolimus has been used in various treatments and has shown effectiveness against different cancers. Patients are monitored for side effects and effectiveness.
Trials for BRAF Positive Patients
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
MEK Inhibitor
Trametinib for Thyroid Cancer
This trial studies the effectiveness of trametinib in increasing iodine uptake in patients with thyroid cancer that has returned or spread. Trametinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and may help make treatment with iodine I-131 more effective.
Monoclonal Antibodies
Atezolizumab + Chemotherapy for Thyroid Cancer
This trial is testing a combination of atezolizumab and chemotherapy in patients with aggressive thyroid cancer. The treatment aims to boost the immune system and stop cancer cell growth. Atezolizumab helps enhance the immune response against cancer cells.
MEK Inhibitor
Selumetinib + Olaparib for Cancer
This trial has two phases: in the first, they'll find the highest dose of the drugs that patients can tolerate; in the second, they'll see if that dose can help control patients' advanced or recurrent solid tumors. Safety will also be monitored in both phases.
Trials With No Placebo
Protein Kinase Inhibitor
Dabrafenib + Lapatinib for Thyroid Cancer
This trial is testing the combination of lapatinib and dabrafenib in patients with hard-to-treat thyroid cancer. The drugs work by blocking proteins that help cancer cells grow. The goal is to find the best dose and observe any anti-tumor activity. Dabrafenib has shown antitumor activity in various cancers, including thyroid cancer, and lapatinib is a tyrosine kinase inhibitor used in breast cancer treatment.
Kinase Inhibitor
Everolimus + Sorafenib for Thyroid Cancer
This trial is testing a combination of two pills, sorafenib and everolimus, to treat thyroid cancer. Sorafenib cuts off the tumor's blood supply, while everolimus blocks a protein that helps cancer cells grow. Everolimus is approved for various cancers, including breast cancer, and has shown promise in combination therapies. The study aims to see if this combination works better than current treatments.
View More Related Trials
Frequently Asked Questions
Introduction to thyroid cancer
What are the top hospitals conducting thyroid cancer research?
When it comes to cutting-edge clinical trials in the realm of thyroid cancer, several renowned hospitals are leading the way. In New york City, Memorial Sloan Kettering Cancer Center is revolutionizing research with an impressive 21 active thyroid cancer trials. While they have not conducted any previous studies specifically focused on this condition, their dedication to exploring new treatments offers hope for patients and sets the stage for groundbreaking discoveries. Similarly, M D Anderson Cancer Center in Houston boasts 17 ongoing trials dedicated to advancing our understanding and treatment options for thyroid cancer.
Moving along the East Coast, Dana-Farber Cancer Institute in Boston is also making significant contributions with eight active clinical trials aimed at improving outcomes for those affected by thyroid cancer. Although this institution has not previously conducted any specific thyroid cancer studies, their commitment to innovation positions them as a force within the field.
In Houston's University of Texas MD Anderson Cancer Center and Rochester's Mayo Clinic, both institutions have begun delving into the world of thyroid cancer research more recently. With seven ongoing trials each at these hospitals, they are actively investigating new avenues and potential breakthroughs that may shape future treatment approaches. Both centers initially embarked on their pioneering journeys into this particular type of trial in 2017.
These top hospitals stand as beacons of hope for individuals battling against thyroid cancer across different locations throughout America; all united by a common goal: finding more effective treatments while striving towards improved patient outcomes . Their relentless pursuit of knowledge and dedication to medical advancements offer promise that one day we will conquer this complex disease
Which are the best cities for thyroid cancer clinical trials?
Houston, Texas; New york, New York; Los Angeles, California; Boston, Massachusetts; and Philadelphia, Pennsylvania are among the best cities for thyroid cancer clinical trials. These cities offer a significant number of active trials focused on investigating various treatments such as Pembrolizumab, cabozantinib, LOXO-292, pralsetinib (BLU-667), Vemurafenib, Nivolumab, and more. Through these trials, researchers aim to advance our understanding of thyroid cancer treatment options and potentially improve outcomes for patients facing this disease.
Which are the top treatments for thyroid cancer being explored in clinical trials?
[Thyroid cancer](https://www.withpower.com/clinical-trials/thyroid-cancer) research is rapidly advancing, with notable treatments emerging in current clinical trials. One such treatment is Vemurafenib, currently being explored in two active trials for thyroid cancer. Despite its recent entry into the scene in 2020, it has already shown promising potential with a total of two all-time clinical trials dedicated to this specific type of cancer. As researchers continue their diligent efforts, there is hope that Vemurafenib and other innovative treatments will pave the way towards improved outcomes for patients battling thyroid cancer.
What are the most recent clinical trials for thyroid cancer?
Recent clinical trials offer a beacon of hope for individuals battling thyroid cancer. Amongst the latest advancements is a Phase 2 trial aimed at patients with radioiodine-refractory, recurrent, and/or metastatic differentiated thyroid cancer (DTC). This study explores innovative treatment options to address this challenging subtype of thyroid cancer. Another trial focuses on DB-1202 Dose Expansion 3, which investigates potential therapeutic benefits in patients with thyroid cancer through both Phase 1 and Phase 2 stages. Additionally, a Phase 1 Dose Expansion trial showcases promising developments in the field by evaluating new approaches for treating thyroid cancer. These groundbreaking studies bring us closer to improved outcomes and enhanced care for those affected by this disease.
What thyroid cancer clinical trials were recently completed?
Recently completed clinical trials in the field of thyroid cancer have made significant strides towards advancing treatment options. Notably, a trial sponsored by the National Cancer Institute (NCI) investigated the efficacy of a novel targeted therapy and concluded successfully. The results are encouraging for patients with thyroid cancer as they offer potential avenues for improved management of this complex disease.